Our company's imported active pharmaceutical ingredient (API) Furosemide has officially received marketing approval from the National Medical Products Administration (NMPA). Covering injectable and oral formulations, the product meets international quality standards, providing domestic formulation manufacturers with a stable, compliant supply of high-quality API. Committed to professionalism and efficiency, we continue to source premium imported APIs to support our partners in accelerating R&D and regulatory filing. Pharmaceutical enterprises and R&D institutions are welcome to explore collaboration opportunities.

We are pleased to announce that Lunarsun Pharma's Vonoprazan Fumarate Tablets have obtained NMPA marketing authorization. Against a rising global burden of acid-related diseases, effective treatments delivering rapid, durable symptom relief remain highly sought-after. As a P-CAB, Vonoprazan outperforms conventional PPIs with key clinical strengths: • Faster onset of acid suppression • Potent, sustained gastric acid control • Minimal influence from CYP2C19 genetic polymorphism • Flexible dosing without strict pre-meal intake Our fully integrated API and finished dosage manufacturing ecosystem ensures stable supply, competitive costs and sustainable commercial cooperation. We welcome partnerships covering the GCC, Middle East, Africa, Southeast Asia, Latin America and other emerging markets. Reach out to discuss collaboration opportunities.

Chongqing Saintsun Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Lunarsun Pharmaceutical, has officially obtained the Drug Registration Certificate for its developed product Sodium Thiosulfate Injection on June 30, 2026.. Approval Number:  国药准字H20265042 This drug is a first-line clinical emergency antidote, which is routinely stocked in hospitals, so it has a steady market demand. We sincerely welcome inquiries and cooperation opportunities.

Vonoprazan Fumarate API Import Registration Approved by NMPA China! This is another product successfully registered in China by Lunarsun Pharma, with over 20 years of dedication to cooperation between Chinese and foreign pharmaceutical industries, for its Indian partner.

CPHI China 2026 – Shanghai Lunarsun warmly welcomes you to the World Pharmaceutical Ingredients Exhibition! Date: June 16–18, 2026 Address: Shanghai New International Expo Centre (SNIEC), Pudong Booth No.: W4Q02 We sincerely invite both new and existing partners to visit us for business discussions!

Recently, Moxifloxacin Hydrochloride Tablets (National Drug Approval No. H20264233), developed and held by our wholly-owned subsidiary Chongqing Saintsun Pharmaceutical Technology Co., Ltd., have been officially approved for marketing by the National Medical Products Administration (NMPA). Moxifloxacin Hydrochloride Tablets represent another approved antibiotic product following Tigecycline for Injection and Moxifloxacin Hydrochloride and Sodium Chloride Injection.

The two antibiotic products, Tigecycline for Injection and Moxifloxacin Hydrochloride Sodium Chloride Injection, began commercial production and were approved for sale this year. They are the first two of formulation products that our wholly-owned subsidiary Chongqing Saintsun has developed, commercially produced and initiated the marketing.

CPHI China 2025 – Shanghai Lunarsun warmly welcomes you to the World Pharmaceutical Ingredients Exhibition! Date: June 24–26, 2025 Address: Shanghai New International Expo Centre (SNIEC), Pudong Booth No.: W4 Q02 We sincerely invite both new and existing partners to visit us for business discussions!  

Our website have a revision and upgrade. The new one is launched on December 26,2024.